BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

459 related articles for article (PubMed ID: 30623817)

  • 1. Comprehensive assessment of T cell receptor β repertoire in Stevens-Johnson syndrome/toxic epidermal necrolysis patients using high-throughput sequencing.
    Xiong H; Wang L; Jiang M; Chen S; Yang F; Zhu H; Zhu Q; Tang C; Qin S; Xing Q; Luo X
    Mol Immunol; 2019 Feb; 106():170-177. PubMed ID: 30623817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome.
    Ko TM; Chung WH; Wei CY; Shih HY; Chen JK; Lin CH; Chen YT; Hung SI
    J Allergy Clin Immunol; 2011 Dec; 128(6):1266-1276.e11. PubMed ID: 21924464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic markers and danger signals in stevens-johnson syndrome and toxic epidermal necrolysis.
    Chung WH; Hung SI
    Allergol Int; 2010 Dec; 59(4):325-32. PubMed ID: 20962567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the genetics and immunology of Stevens-Johnson syndrome and toxic epidermal necrosis.
    Chung WH; Hung SI
    J Dermatol Sci; 2012 Jun; 66(3):190-6. PubMed ID: 22541332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbamazepine Induces Focused T Cell Responses in Resolved Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Cases But Does Not Perturb the Immunopeptidome for T Cell Recognition.
    Mifsud NA; Illing PT; Lai JW; Fettke H; Hensen L; Huang Z; Rossjohn J; Vivian JP; Kwan P; Purcell AW
    Front Immunol; 2021; 12():653710. PubMed ID: 33912179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural modeling of HLA-B*1502/peptide/carbamazepine/T-cell receptor complex architecture: implication for the molecular mechanism of carbamazepine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Zhou P; Zhang S; Wang Y; Yang C; Huang J
    J Biomol Struct Dyn; 2016 Aug; 34(8):1806-17. PubMed ID: 26488421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-johnson Syndrome and Toxic Epidermal Necrolysis: An Overview of Diagnosis, Therapy Options and Prognosis of Patients.
    Garg VK; Buttar HS; Bhat SA; Ainur N; Priya T; Kashyap D; Tuli HS
    Recent Adv Inflamm Allergy Drug Discov; 2023; 17(2):110-120. PubMed ID: 37605396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Cristallo AF; Schroeder J; Citterio A; Santori G; Ferrioli GM; Rossi U; Bertani G; Cassano S; Gottardi P; Ceschini N; Barocci F; Ribizzi G; Cutrupi V; Cairoli R; Rapisarda V; Pastorello EA; Barocci S
    Int J Immunogenet; 2011 Aug; 38(4):303-9. PubMed ID: 21545408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA-B*1502 strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain.
    Kulkantrakorn K; Tassaneeyakul W; Tiamkao S; Jantararoungtong T; Prabmechai N; Vannaprasaht S; Chumworathayi P; Chen P; Sritipsukho P
    Pain Pract; 2012 Mar; 12(3):202-8. PubMed ID: 21676164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between HLA-B*5901 and methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis.
    Tangamornsuksan W; Lohitnavy M
    Pharmacogenomics J; 2019 Jun; 19(3):286-294. PubMed ID: 30242287
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome.
    Wei CY; Chung WH; Huang HW; Chen YT; Hung SI
    J Allergy Clin Immunol; 2012 Jun; 129(6):1562-9.e5. PubMed ID: 22322005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population.
    Tassaneeyakul W; Jantararoungtong T; Chen P; Lin PY; Tiamkao S; Khunarkornsiri U; Chucherd P; Konyoung P; Vannaprasaht S; Choonhakarn C; Pisuttimarn P; Sangviroon A; Tassaneeyakul W
    Pharmacogenet Genomics; 2009 Sep; 19(9):704-9. PubMed ID: 19696695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Stevens-Johnson syndrome and toxic epidermal necrolysis--updates and innovations].
    Halevy S
    Harefuah; 2010 Mar; 149(3):186-90, 193. PubMed ID: 20684173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Abe R
    J Dermatol; 2015 Jan; 42(1):42-8. PubMed ID: 25355273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies.
    Lin CC; Chen CB; Wang CW; Hung SI; Chung WH
    Expert Rev Clin Immunol; 2020 Apr; 16(4):373-387. PubMed ID: 32154748
    [No Abstract]   [Full Text] [Related]  

  • 16. HLA-B*5901 is strongly associated with methazolamide-induced Stevens-Johnson syndrome/toxic epidermal necrolysis.
    Kim SH; Kim M; Lee KW; Kim SH; Kang HR; Park HW; Jee YK
    Pharmacogenomics; 2010 Jun; 11(6):879-84. PubMed ID: 20504258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. T-cell receptor and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: understanding a hypersensitivity reaction.
    Ko TM; Chen YT
    Expert Rev Clin Immunol; 2012 Jul; 8(5):467-77. PubMed ID: 22882221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.
    Lonjou C; Borot N; Sekula P; Ledger N; Thomas L; Halevy S; Naldi L; Bouwes-Bavinck JN; Sidoroff A; de Toma C; Schumacher M; Roujeau JC; Hovnanian A; Mockenhaupt M;
    Pharmacogenet Genomics; 2008 Feb; 18(2):99-107. PubMed ID: 18192896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Mechanisms of Severe Cutaneous Adverse Reactions and a New Treatment Strategy].
    Saito Y; Nakamura R
    Yakugaku Zasshi; 2019; 139(12):1557-1562. PubMed ID: 31787645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.